This discovery emphasizes the biological heterogeneity within HER2-negative breast cancer, as HER2-low tumors show sensitivity to next-generation anti-HER2 antibody-drug conjugates such as trastuzumab deruxtecan (11). Here, ERBB2 is linked to breast carcinoma.